FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Significantly higher association between diabetes and VTE seen among women versus men, especially those aged 50 to 59 years
Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Odds of major postoperative cardiovascular morbidity reduced with increased time from COVID-19 diagnosis to surgery
Largest effect sizes seen for venous thromboembolism, heart failure, and stroke; risks highest in first 30 days
A study was conducted to determine the relationship between COVID-19 severity and risk for cardiovascular events 30 days following diagnosis.
Improvement seen with electronic alert-triggered, patient-centered education bundle intervention or nurse feedback intervention
Incidence is highest in first week, but remains elevated up to 49 weeks after COVID-19 diagnosis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
The increased risk for venous thromboembolism with an arteriovenous graft is one factor for clinicians and patients to consider in the choice of vascular access for hemodialysis.